Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
11.01
USD
|
-9.61%
|
|
-17.47%
|
-51.50%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
335.8
|
300.2
|
107.4
|
269.6
|
972.7
|
531.2
|
-
|
-
|
Enterprise Value (EV)
1 |
199.6
|
191.6
|
-14.85
|
163
|
972.7
|
273.4
|
350.5
|
305.6
|
P/E ratio
|
-3.43
x
|
-8.67
x
|
-2.11
x
|
-5.11
x
|
-13.8
x
|
-5.82
x
|
-5.22
x
|
-5.06
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
95.6
x
|
283
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
63.1
x
|
163
x
|
EV / EBITDA
|
-10.7
x
|
-5.72
x
|
0.33
x
|
-3.06
x
|
-13.3
x
|
-2.85
x
|
-3.18
x
|
-2.4
x
|
EV / FCF
|
-11.9
x
|
-6.99
x
|
0.42
x
|
-3.34
x
|
-
|
-3.07
x
|
-4.2
x
|
-2.77
x
|
FCF Yield
|
-8.39%
|
-14.3%
|
238%
|
-30%
|
-
|
-32.5%
|
-23.8%
|
-36.1%
|
Price to Book
|
2.43
x
|
2.74
x
|
0.93
x
|
2.6
x
|
-
|
2.73
x
|
4.63
x
|
3.02
x
|
Nbr of stocks (in thousands)
|
24,034
|
24,055
|
28,332
|
29,141
|
42,849
|
48,249
|
-
|
-
|
Reference price
2 |
13.97
|
12.48
|
3.790
|
9.250
|
22.70
|
11.01
|
11.01
|
11.01
|
Announcement Date
|
30/03/20
|
16/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
5.556
|
1.875
|
EBITDA
1 |
-18.58
|
-33.48
|
-45.52
|
-53.18
|
-73.23
|
-95.76
|
-110.1
|
-127.4
|
EBIT
1 |
-18.68
|
-33.83
|
-46.31
|
-54.14
|
-74.66
|
-98.52
|
-112.6
|
-138.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-2,027.57%
|
-7,388.03%
|
Earnings before Tax (EBT)
1 |
-16.94
|
-33.34
|
-46.29
|
-52.98
|
-67.68
|
-92.4
|
-108.7
|
-136.6
|
Net income
1 |
-22.27
|
-33.34
|
-46.29
|
-52.98
|
-67.68
|
-92.39
|
-108.7
|
-136.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,957.38%
|
-7,284.45%
|
EPS
2 |
-4.070
|
-1.440
|
-1.800
|
-1.810
|
-1.650
|
-1.892
|
-2.110
|
-2.177
|
Free Cash Flow
1 |
-16.74
|
-27.4
|
-35.28
|
-48.83
|
-
|
-88.97
|
-83.48
|
-110.4
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,502.55%
|
-5,885.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
16/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-22.81
|
-23.28
|
-24.07
|
-25.06
|
-26.06
|
-
|
EBIT
1 |
-11.56
|
-13.89
|
-13
|
-13.06
|
-11.78
|
-16.3
|
-16.96
|
-15.89
|
-18.67
|
-23.15
|
-22.96
|
-24.11
|
-25.28
|
-26.4
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-11.56
|
-13.89
|
-12.95
|
-12.91
|
-11.43
|
-15.69
|
-15.85
|
-14.49
|
-16.45
|
-20.89
|
-21.35
|
-22.57
|
-23.78
|
-24.92
|
-
|
Net income
1 |
-11.56
|
-13.89
|
-12.95
|
-12.91
|
-11.43
|
-15.69
|
-15.85
|
-14.49
|
-16.45
|
-20.89
|
-21.35
|
-22.57
|
-23.78
|
-24.93
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4500
|
-0.4900
|
-0.4500
|
-0.4500
|
-0.3900
|
-0.5200
|
-0.4500
|
-0.3700
|
-0.3700
|
-0.4600
|
-0.4756
|
-0.4722
|
-0.4700
|
-0.4822
|
-0.6700
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/11/21
|
17/03/22
|
12/05/22
|
11/08/22
|
10/11/22
|
16/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
21/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
136
|
109
|
122
|
107
|
-
|
258
|
181
|
226
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-16.7
|
-27.4
|
-35.3
|
-48.8
|
-
|
-89
|
-83.5
|
-110
|
ROE (net income / shareholders' equity)
|
-26.6%
|
-26.9%
|
-40.7%
|
-47.6%
|
-
|
-44.2%
|
-56.5%
|
-57.8%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.760
|
4.550
|
4.080
|
3.560
|
-
|
4.040
|
2.380
|
3.640
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.69
|
0.64
|
1.17
|
2.45
|
-
|
0.8
|
4.5
|
7
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
81%
|
373.33%
|
Announcement Date
|
30/03/20
|
16/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
11.01
USD Average target price
34.5
USD Spread / Average Target +213.35% Consensus |
1st Jan change
|
Capi.
|
---|
| -51.50% | 531M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|